Direct Measurement of Nitric Oxide Concentration in CAPD Dialysate

1. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427–43. 2. Vasudevan A, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitisation, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004; 6:850–63. 3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457–71. 4. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370(9593): 1129–36. 5. Lin SH, Kin YF, Kuo SW, Hsu YJ, Hung YJ. Rosiglitazone improves glucose metabolism in non diabetic uremic patients on CAPD. Am J Kidney Dis 2003; 42:774–80. 6. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005; 46:713–18. 7. Haraldsson B. Assessing the individual peritoneal dialysis capacities of individual patients. A clinical tool based on the three pore model. Kidney Int 1995; 47:1187–98. 8. La Milia V, Pozzoni P, Virga G, Crepaldi M, Del Vecchio L, Andrulli S, et al. Peritoneal transport assessment by PET with 3.86% glucose: a long-term prospective evaluation. Kidney Int 2006; 69:927–33. 9. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006; 17:3482–90. 10. Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich) 2006; 8:19–28. 11. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, et al. Blood pressure lowering by pioglitazone, evidence for a direct vascular effect. J Clin Invest 1995, 96:354–60. 12. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase the release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23:52–7. 13. Maziere C, Meignotte A, Dantin F, Conte MA, Maziere JC. Oxidized LDL induces an oxidative stress and activates the tumor suppressor P53 in MRC5 human fibroblasts. Biochem Biophys Res Commun 2000; 276:718–23.